Sep 23, 2023
Dr. Matthew Powell, professor of obstetrics and gynecology and Chief of the Gynecological Oncology Division at Washington University. He was also a clinical investigator in the pivotal trial leading to the approval of Jemperli, a treatment for endometrial cancer. This is an immunotherapy drug that works well for...
Sep 23, 2023
Dr. Matthew Powell, professor of obstetrics and gynecology and Chief of the Gynecological Oncology Division at Washington University. He was also a clinical investigator in the pivotal trial leading to the approval of Jemperli, a treatment for endometrial cancer. This is an immunotherapy drug that works well for...
Aug 28, 2023
Dave Hering, Chief Executive Officer and Director at Invivyd, draws on his experience with vaccines working at Pfizer and research on monoclonal antibodies to engineer targeted monoclonal antibodies to treat diseases like cancer and prevent diseases like COVID-19. Providing antibodies, particularly to immunocompromised...
Aug 28, 2023
Dave Hering, Chief Executive Officer and Director at Invivyd, draws on his experience with vaccines working at Pfizer and research on monoclonal antibodies to engineer targeted monoclonal antibodies to treat diseases like cancer and prevent diseases like COVID-19. Providing antibodies, particularly to immunocompromised...
Jul 24, 2023
Jeff Hackman, CEO of Comera Life Sciences, recognizes the need to find a more efficient, patient-friendly solution for receiving biologics rather than being administered by IV therapy. Using the SQore platform, a proprietary technology, Comera is reformulating IV biologics to Sub-Q utilizing small molecule chemistry...